Bill Details

HR.1796 - 119th Congress

Track Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025? Stop tracking Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025?

When you track this bill you will receive emails when the bill has been updated.

You will no longer receive emails when this bill is updated.

Status
  1. Introduced
  2. Passed House
  3. Passed Senate
  4. To President
  5. Law
Latest action
2025-03-03 - Referred to the House Committee on Energy and Commerce.
Introduced Date
2025-03-03
Policy Area
Health
Committees
6
0

Official Summaries

No summaries available

Current Full Text

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1796 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 1796

  To amend the Public Health Service Act to reauthorize a sickle cell 
        disease prevention and treatment demonstration program.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 3, 2025

Mr. James (for himself, Mr. Veasey, Mr. Carter of Louisiana, Mr. Davis 
  of Illinois, and Mrs. Kiggans of Virginia) introduced the following 
    bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
  To amend the Public Health Service Act to reauthorize a sickle cell 
        disease prevention and treatment demonstration program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Sickle Cell Disease and Other 
Heritable Blood Disorders Research, Surveillance, Prevention, and 
Treatment Act of 2025''.

SEC. 2. SICKLE CELL DISEASE TREATMENT PREVENTION AND TREATMENT.

    (a) In General.--Section 1106(b) of the Public Health Service Act 
(42 U.S.C. 300b-5(b)) is amended--
            (1) in paragraph (1)(A)(iii), by striking ``prevention and 
        treatment of sickle cell disease'' and inserting ``treatment of 
        sickle cell disease and the prevention and treatment of 
        complications of sickle cell disease'';
            (2) in paragraph (2)(D), by striking ``prevention and 
        treatment of sickle cell disease'' and inserting ``treatment of 
        sickle cell disease and the prevention and treatment of 
        complications of sickle cell disease'';
            (3) in paragraph (3)--
                    (A) in subparagraph (A), by striking ``enter into a 
                contract with'' and inserting ``make a grant to, or 
                enter into a contract or cooperative agreement with,''; 
                and
                    (B) in subparagraph (B), in each of clauses (ii) 
                and (iii), by striking ``prevention and treatment of 
                sickle cell disease'' and inserting ``treatment of 
                sickle cell disease and the prevention and treatment of 
                complications of sickle cell disease''; and
            (4) in paragraph (6), by striking ``$4,455,000 for each of 
        fiscal years 2019 through 2023'' and inserting ``$8,205,000 for 
        each of fiscal years 2025 through 2029''.
    (b) Sense of Congress.--It is the sense of Congress that further 
research should be undertaken to expand the understanding of the causes 
of, and to find cures for, heritable blood disorders, including sickle 
cell disease.
                                 <all>